BioCryst Pharmaceuticals
-
BCRX challenges Biota patent, claims its hepatitis C compound was first
The experimental hepatitis C treatment that BioCryst Pharmaceuticals (NASDAQ:BCRX) wants to take into clinical trials […]
-
Hepatitis C compound from BioCryst set for 4Q IND filing
The investigational hepatitis C treatment under development by BioCryst Pharmaceuticals (NASDAQ:BCRX) is now ready to […]
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Former Roche executive Abercrombie named to BioCryst board
Former Roche executive George Abercrombie has been elected to BioCryst Pharmaceuticals‘ (NASDAQ:BCRX) board of directors, […]